Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as an observational study.

The assessment of the disease burden is complex, and among others, tools such as the allodynia symptoms checklist (ASC-12) and headache impact test (HIT-6) are very useful.

This exploratory study analysed the impact of these two therapies on migraine burden.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

This study involved patients with chronic migraine treated with mAbs or BoNT-A.

How the Study Was Run

The researchers set it up as a multicenter study.

More than one site took part, so the participants came from several places.

The RAMO study was a multicentre, observational, retrospective investigation conducted in two headache centres: the Fondazione IRCCS Istituto Neurologico Carlo Besta (Milan) and the Fondazione Policlinico Campus Bio-Medico (Rome).

The researchers conducted a subgroup exploratory analysis on HIT-6 and ASC-12 scores in the two groups.

The Wilcoxon rank-sum test, Fisher's exact test, and ANOVA were performed.

What Was Measured

The assessment of the disease burden is complex, and among others, tools such as the allodynia symptoms checklist (ASC-12) and headache impact test (HIT-6) are very useful.

The subject headings attached to it are Botulinum Toxins, Type A, Migraine Disorders, Antibodies, Monoclonal, Hyperalgesia, Calcitonin Gene-Related Peptide and Chronic Disease.

Author keywords: ASC-12, HIT-6, allodynia, erenumab, fremanezumab and galcanezumab.

What This Means in Plain Language

The paper is a multicenter study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Toxins), a journal based in Switzerland.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.